Namibia Business News API

{
    "totalArticles": 3137,
    "articles": [
        {
            "id": "357b32fe34598387fb42457f76058351",
            "title": "BOSS, JIAREN CHEMICAL RECYCLING, AND NBC LLC INTRODUCE NOVAPOLY™ YARN ON THE COURTS IN MELBOURNE",
            "description": "BOSS, JIAREN CHEMICAL RECYCLING, AND NBC LLC INTRODUCE NOVAPOLY™ YARN ON THE COURTS IN MELBOURNE",
            "content": "This month, at the year’s first major international tennis tournament, BOSS is proud to debut NovaPoly™ yarn: a recycled alternative to virgin polyester with the potential to inspire industry progress in textile innovation and advanced performance, d... [5489 chars]",
            "url": "https://group.hugoboss.com/en/newsroom/news/news-detail/boss-jiaren-chemical-recycling-and-nbc-llc-introduce-novapolytm-yarn-on-the-courts-in-melbourne",
            "image": "https://group.hugoboss.com/fileadmin/_processed_/b/a/csm_SpringSummer2026_BOSS_NovaPoly_Yarn_Taylor_Fritz__original_klein_526920d5cd.jpg",
            "publishedAt": "2026-01-13T17:42:42Z",
            "lang": "en",
            "source": {
                "id": "d3ee9d205f90d894765630bb7984b00f",
                "name": "HUGO BOSS Group",
                "url": "https://group.hugoboss.com"
            }
        },
        {
            "id": "43d03880677e5c8962fa23f7fe23dbc4",
            "title": "FDA Accepts sBLA for Ropeginterferon-Alfa-2b for Essential Thrombocythemia",
            "description": "A target action date of August 30, 2026, has been set for the FDA's decision regarding the sBLA seeking the approval of ropeginterferon alfa-2b for ET.",
            "content": "The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of ropeginterferon alfa-2b-njft (Besremi) for the treatment of adult patients with essential thrombocythemia (ET).1\nFDA sBLA Acceptance for Ropeginterferon-... [4696 chars]",
            "url": "https://www.onclive.com/view/fda-accepts-sbla-for-ropeginterferon-alfa-2b-for-essential-thrombocythemia",
            "image": "https://cdn.sanity.io/images/0vv8moc6/onclive/4532fbaebbca96a6a96d9051297abfa19c96ace7-1280x720.jpg",
            "publishedAt": "2026-01-13T17:00:51Z",
            "lang": "en",
            "source": {
                "id": "0da2d0b1fc86b8b05e122c750c98bd32",
                "name": "OncLive",
                "url": "https://www.onclive.com"
            }
        },
        {
            "id": "92f99147ee3c1e84d6ae818d1665313f",
            "title": "JPMorgan is lower after better-than-expected results. Is it a buying opportunity?",
            "description": "Wall Street analysts largely framed the pullback as profit-taking rather than a fundamental shift in the outlook.",
            "content": "JPMorgan Chase shares were under pressure Tuesday despite a strong quarter , and Wall Street analysts largely framed the pullback as profit-taking rather than a fundamental shift in the outlook. The bank stock fell nearly 3% on Tuesday after the bank... [2356 chars]",
            "url": "https://www.cnbc.com/2026/01/13/jpmorgan-is-lower-after-better-than-expected-results-is-it-a-buying-opportunity.html",
            "image": "https://image.cnbcfm.com/api/v1/image/108225852-1763076093763-gettyimages-2246002629-AFP_83YT9HU.jpeg?v=1768319883&w=1920&h=1080",
            "publishedAt": "2026-01-13T16:32:53Z",
            "lang": "en",
            "source": {
                "id": "32c2ad3fb41cb87b5b847d750028dff0",
                "name": "CNBC",
                "url": "https://www.cnbc.com"
            }
        }
    ]
}